Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy

被引:1
|
作者
Laliscia, Concetta [1 ]
Coccia, Natalina [1 ]
Fuentes, Taiusha [1 ]
Perrone, Franco [2 ]
Paiar, Fabiola [1 ]
机构
[1] Univ Pisa, Dept New Technol & Translat Res, Div Radiat Oncol, Via Roma 67, I-56127 Pisa, Italy
[2] Univ Pisa, Med Phys Dept, Pisa, Italy
关键词
non-melanoma skin cancer; brachytherapy; Valencia applicator; BASAL-CELL CARCINOMA; STANDARDIZED SURFACE APPLICATORS; RADIATION-THERAPY; HDR BRACHYTHERAPY; GUIDELINES; RECURRENCE;
D O I
10.5114/jcb.2021.112111
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this retrospective study was to analyze tumor control, toxicity, and aesthetic outcome of patients affected by non-melanoma skin cancer (NMSC) and treated with iridium-192 (192Ir) high-dose-rate (HDR) brachytherapy (BT) using Valencia applicators at the Division of Radiotherapy, University of Pisa. Material and methods: From June 2015 to December 2020, 95 NMSC patients, including 61.5% basal cell carcinoma and 38.5% squamous cell carcinoma patients, with median age of 83 years (range, 32-96 years) were treated. In total, 182 lesions with a diameter <= 25 mm (median, 12 mm) and a depth <= 4 mm, located in scalp (19.2%), face (20.9%), chest (8.8%), nose (16.5%), ear (15.4%), and extremities (19.2%) were analyzed. All lesions were treated with 192Ir-based HDR afterloader using Valencia applicators. 105 lesions (57.7%) were treated with applicator of 20 mm and 77 lesions (42.3%) with applicator of 30 mm in diameter, depending on the size of lesions. Prescribed dose was 40 Gy in 8 fractions (5 Gy/fraction) delivered 2-3 times a week. Biological effective dose (BED) was approximate to 60 Gy. Results: The median follow-up was 14 months (range, 3-59 months). The 2-year local control rate was 96%. According to common terminology criteria for adverse events (CTCAE v. 5.0), G1-G2 acute toxicities included dermatitis (22.0%) and pain (8.2%). The most common G1 late toxicities were hypopigmentation (27.5%) and fibrosis (8.2%), and G2 late toxicity included ulceration (0.5%). No G3 or higher acute or late toxicities were reported. Excellent cosmetic results were observed in 77.5% of the lesions, with one only (0.5%) reported as a poor cosmetic result (ulceration refractory to therapy). Conclusions: HDR-BT using Valencia applicators is a safe, effective, and well-tolerated treatment modality for NMSC, and can be considered a good alternative for treatment, especially in elderly patients who are often unfit for surgery.
引用
收藏
页码:615 / 619
页数:5
相关论文
共 50 条
  • [21] Implementation of high dose rate (HDR) skin brachytherapy using the Valencia applicator: Leeds Cancer Centre non-melanoma cohort
    Boon, Ian S.
    Bownes, Peter
    Namini, Shirin
    Richardson, Carolyn
    Ramasamy, Satiavani
    CLINICAL ONCOLOGY, 2019, 31 : E15 - E15
  • [22] Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy
    Scherf, Christian
    Ramm, Ulla
    Stein, Thomas
    Trommel, Martin
    Tselis, Nikolaos
    Chatzikonstantinou, Georgios
    Diefenhardt, Markus
    Roedel, Claus
    Koehn, Janett
    Licher, Joerg
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (01) : 80 - 86
  • [23] High-dose-rate brachytherapy in treatment of non-melanoma skin cancer of head and neck region: preliminary results of a prospective single institution study
    Kalaghchi, Bita
    Esmati, Ebrahim
    Ghalehtaki, Reza
    Gomar, Marzieh
    Jaberi, Ramin
    Gholami, Soraya
    Babaloui, Somayyeh
    Nabavi, Mansoureh
    Sotoudeh, Sarvazad
    Khanjani, Nezhat
    Kazemian, Ali
    Amouzegar-Hashemi, Farnaz
    Aghili, Mahdi
    Lashkari, Marzieh
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2018, 10 (02) : 115 - 122
  • [24] High-dose-rate brachytherapy for the treatment of nonmelanoma skin cancer
    Huang, Ya-Yun
    Lan, Cheng-Che
    Tang, Jen-Yang
    DERMATOLOGICA SINICA, 2019, 37 (04) : 233 - 234
  • [25] High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer
    Ángel Montero
    Raúl Hernanz
    Ana-Belén Capuz
    Eva Fernández
    Asunción Hervás
    Rafael Colmenares
    Alfredo Polo
    Sonsoles Sancho
    Rafael Molerón
    Carmen Vallejo
    Alfredo Ramos
    Clinical and Translational Oncology, 2009, 11 : 760 - 764
  • [26] High-dose-rate brachytherapy for non-melanoma skin cancer using tailored custom moulds - a single-centre experience
    Laliscia, Concetta
    Fuentes, Taiusha
    Coccia, Natalina
    Mattioni, Roberto
    Perrone, Franco
    Paiar, Fabiola
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2021, 25 (01): : 12 - 16
  • [27] High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer
    Montero, Angel
    Hernanz, Raul
    Capuz, Ana-Belen
    Fernandez, Eva
    Hervas, Asuncion
    Colmenares, Rafael
    Polo, Alfredo
    Sancho, Sonsoles
    Moleron, Rafael
    Vallejo, Carmen
    Ramos, Alfredo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11): : 760 - 764
  • [28] Determination of the tissue inhomogeneity correction in high dose rate Brachytherapy for Iridium-192 source
    Ravikumar, Barlanka
    Lakshminarayana, S.
    JOURNAL OF MEDICAL PHYSICS, 2012, 37 (01) : 27 - 31
  • [29] Iridium 192 high-dose-rate brachytherapy - a useful alternative therapy for localized prostate cancer?
    Paul, R
    Hofmann, R
    Schwarzer, JU
    Stepan, R
    Feldmann, HJ
    Kneschaurek, P
    Molls, M
    Hartung, R
    WORLD JOURNAL OF UROLOGY, 1997, 15 (04) : 252 - 256
  • [30] Iridium 192 high-dose-rate brachytherapy —a useful alternative therapy for localized prostate cancer?
    R. Paul
    R. Hofmann
    J. U. Schwarzer
    R. Stepan
    H. J. Feldmann
    P. Kneschaurek
    M. Molls
    R. Hartung
    World Journal of Urology, 1997, 15 : 252 - 256